Ceo dr. johnson lau contracts covid-19

Buffalo, n.y., jan. 08, 2021 (globe newswire) -- athenex, inc., (nasdaq: atnx), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that its ceo and board chairman, dr. johnson lau, has contracted covid-19. dr. lau is receiving oral and intravenous treatment at a local hospital, and his condition is currently stable. dr. lau is communicating with senior management and continues to serve as athenex's ceo. under the advice of his physician, he will not be able to attend the 39th annual j.p. morgan healthcare conference. athenex's senior management team will continue to participate and present at the 39th annual j.p. morgan healthcare conference at its previously scheduled presentation time, and investor one-on-one meetings.
ATNX Ratings Summary
ATNX Quant Ranking